Filtered By:
Condition: Arthritis
Drug: Hydroxychloroquine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 22 results found since Jan 2013.

A 6-Step Rapid Desensitization Protocol to Hydroxychloroquine
Hydroxychloroquine, a 4-amino-quinolone antimalarial medication, is widely used for the treatment of systemic lupus erythematosus (SLE), discoid lupus erythematosus (DLE), rheumatoid arthritis and related inflammatory conditions. Cutaneous adverse reactions typically develop within 2-33 days and manifest as type IV reactions typically as a maculopapular exanthem (MPE)1. Type 1 reactions resulting in urticaria and anaphylaxis are less commonly reported in the literature2. It is estimated that 10% of patients on hydroxychloroquine will develop a hypersensitivity reaction resulting in its discontinuation3.
Source: Annals of Allergy, Asthma and Immunology - December 1, 2020 Category: Allergy & Immunology Authors: Kathryn M. Sutton, Suran L. Fernando Tags: Letters Source Type: research

Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

President Trump Called Hydroxychloroquine a ‘Game Changer,’ But Experts Warn Against Self-Medicating With the Drug. Here’s What You Need to Know
After President Trump, late last week, expressed great confidence in the promise of a new COVID-19 therapy that combines two existing prescription medications, supplies of these two drugs rapidly began disappearing from pharmacy shelves. The U.S. Food and Drug Administration allowed an Indian company previously restricted from importing drug products into the US to now start manufacturing one of the drugs. And U.S. plants began gearing up to produce enough to meet the surge in demand. But in those few days, a few people who began self medicating with the drugs in an effort to prevent COVID-19 have died, and others have bee...
Source: TIME: Health - March 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Systemic Lupus Erythematosus With Isolated Psychiatric Symptoms and Antinuclear Antibody Detection in the Cerebrospinal Fluid
Conclusion: Some patients with psychiatric syndromes and increased ANA titers may suffer from psychiatric variants of SLE, even if the American College of Rheumatology criteria for SLE are not met. Whether the psychiatric symptoms in our patient represent a prodromal stage with the later manifestation of full-blown SLE or a subtype of SLE with isolated CNS involvement remains unclear. Regardless, early diagnosis and initiation of immunosuppressive treatment are essential steps in preventing further disease progression and organ damage. Intrathecal ANAs with extractable nuclear antigen differentiation may be a more sensitiv...
Source: Frontiers in Psychiatry - April 24, 2019 Category: Psychiatry Source Type: research

Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis
Conclusions In RA, incidence of DM is increased. Hydroxychloroquine and abatacept were associated with decreased risk of DM, and glucocorticoids and statins with increased risk.
Source: Annals of the Rheumatic Diseases - April 6, 2017 Category: Rheumatology Authors: Ozen, G., Pedro, S., Holmqvist, M. E., Avery, M., Wolfe, F., Michaud, K. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase
Conclusions We describe here a novel mechanism of action of HCQ, that is, interference with the assembly of endosomal NOX2. Since endosomal NOX2 is involved in many inflammatory and prothrombotic signalling pathways, this activity of HCQ might explain many of its beneficial effects in rheumatic diseases including the APS.
Source: Annals of the Rheumatic Diseases - April 6, 2017 Category: Rheumatology Authors: Müller-Calleja, N., Manukyan, D., Canisius, A., Strand, D., Lackner, K. J. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Systemic lupus erythematosus, Clinical diagnostic tests Basic and translational research Source Type: research

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)
Conclusions An aggressive triamcinolone and synthetic DMARD treat-to-target strategy in eRA provided excellent 2-year clinical and radiographic disease control independent of adalimumab induction therapy. ES progression was slightly less during and following adalimumab induction therapy. Trial registration number NCT00660647.
Source: Annals of the Rheumatic Diseases - August 9, 2016 Category: Rheumatology Authors: Horslev-Petersen, K., Hetland, M. L., Ornbjerg, L. M., Junker, P., Podenphant, J., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzboll, C. G., Jorgensen, A., Krintel, S. B., Raun, Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research

Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial
Conclusions The influence of early antirheumatic therapy on ACPA seroreversions was markedly different across specificities, and early disappearance of anti-cVim antibodies associated with better radiological outcome. Thus, these data suggest that the disappearance of particular ACPA reactivities may be beneficial in early RA. Trial registration number WHO database at the Karolinska institute: CT20080004; and clinicaltrials.gov: NCT00764725.
Source: Annals of the Rheumatic Diseases - January 11, 2016 Category: Rheumatology Authors: Kastbom, A., Forslind, K., Ernestam, S., Geborek, P., Karlsson, J. A., Petersson, I. F., Saevarsdottir, S., Klareskog, L., van Vollenhoven, R. F., Lundberg, K. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Design, Synthesis and In Vitro Release Studies of Co-drugs for Rheumatoid Arthritis.
Abstract Rheumatoid arthritis (RA) is an autoimmune disease that results in a chronic, systemic inflammation that may affect many tissues and organs, but principally the synovial joints. The tendency for joint destruction is greatest in the early stages of disease hence current trend is to introduce a disease-modifying anti-rheumatic drug (DMARD) immediately after the diagnosis of RA in a step- up approach which is generally followed by its combination with a corticosteroid or NSAID. DMARD suppresses inflammatory activity over a long time-frame thus improving day to day function, and also prevents, lessens or dela...
Source: Inflammation and Allergy Drug Targets - December 1, 2015 Category: Allergy & Immunology Authors: Kashmira P, Suneela D, Shakuntalah C, Poorvashree J Tags: Inflamm Allergy Drug Targets Source Type: research

Ocular Involvement in Systemic Autoimmune Diseases
Abstract Eye involvement represents a common finding in patients with systemic autoimmune diseases, particularly rheumatoid arthritis, Sjogren syndrome, seronegative spondyloarthropathy, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The eye is a privileged immune site but commensal bacteria are found on the ocular surface. The eye injury may be inflammatory, vascular or infectious, as well as iatrogenic, as in the case of hydroxychloroquine, chloroquine, corticosteroids, and bisphosphonates. Manifestations may affect different components of the eye, with episcleritis involving the episclera...
Source: Clinical Reviews in Allergy and Immunology - October 22, 2015 Category: Allergy & Immunology Source Type: research

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial
Conclusions In addition to previously described predictors, we identified smoking as a strong independent risk factor for radiographic progression in early RA. Trial registration number NCT00764725.
Source: Annals of the Rheumatic Diseases - July 9, 2015 Category: Rheumatology Authors: Saevarsdottir, S., Rezaei, H., Geborek, P., Petersson, I., Ernestam, S., Albertsson, K., Forslind, K., van Vollenhoven, R. F., for the SWEFOT study group Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
Conclusions In early, methotrexate-refractory rheumatoid arthritis, a treatment strategy commencing with addition of infliximab, as compared to sulfasalazine+hydroxychloroquine, was not cost-effective over 21 months at willingness to pay levels generally considered acceptable. Trial registration number: NCT00764725.
Source: Annals of the Rheumatic Diseases - May 8, 2015 Category: Rheumatology Authors: Eriksson, J. K., Karlsson, J. A., Bratt, J., Petersson, I. F., van Vollenhoven, R. F., Ernestam, S., Geborek, P., Neovius, M. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Health economics Clinical and epidemiological research Source Type: research

Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use
Conclusions FO was associated with benefits additional to those achieved by combination ‘treat-to-target’ DMARDs with similar MTX use. These included reduced triple DMARD failure and a higher rate of ACR remission.
Source: Annals of the Rheumatic Diseases - December 4, 2014 Category: Rheumatology Authors: Proudman, S. M., James, M. J., Spargo, L. D., Metcalf, R. G., Sullivan, T. R., Rischmueller, M., Flabouris, K., Wechalekar, M. D., Lee, A. T., Cleland, L. G. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial
Conclusions In early RA, targeted treatment with a combination of traditional DMARDs and prednisolone induces remission and minimises radiographic progression in most patients up to 5 years; adding initial infliximab for 6 months does not improve these outcomes.
Source: Annals of the Rheumatic Diseases - October 5, 2014 Category: Rheumatology Authors: Rantalaiho, V., Kautiainen, H., Korpela, M., Hannonen, P., Kaipiainen-Seppanen, O., Mottonen, T., Kauppi, M., Karjalainen, A., Laiho, K., Laasonen, L., Hakola, M., Peltomaa, R., Leirisalo-Repo, M., Alasaarela, Blafield, Eklund, Ilva, Julkunen, Kononoff, K Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

An Update on Disease Modifying Antirheumatic Drugs.
Abstract Disease modifying antirheumatic drugs (DMARDs) is a category of drugs which is used as medication in various arthritic conditions to arrest the progression of disease along with relief from pain. About 83% of population worldwide uses DMARDs. Withdrawal of COX-2 inhibitors because of cardiovascular side effects and short-term action associated with glucocorticoids provided a motivation for development of newer DMARDs. Currently non- biological DMARDs like methotrexate, sulfasalazine, hydroxychloroquine and azathioprine serve the purpose of relieving pain and inhibiting the progression of disease. Biologic...
Source: Inflammation and Allergy Drug Targets - September 23, 2014 Category: Allergy & Immunology Authors: Joshi P, Dhaneshwar SS Tags: Inflamm Allergy Drug Targets Source Type: research